Phio Pharmaceuticals (NASDAQ:PHIO) Posts Earnings Results, Meets Expectations

Phio Pharmaceuticals (NASDAQ:PHIO) issued its quarterly earnings data on Thursday. The company reported ($0.36) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.36), FiscalAI reports.

Phio Pharmaceuticals Stock Performance

Phio Pharmaceuticals stock traded up $0.00 during mid-day trading on Friday, reaching $0.80. 75,619 shares of the company were exchanged, compared to its average volume of 1,327,135. Phio Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $1.88. The firm’s 50-day simple moving average is $0.98 and its two-hundred day simple moving average is $1.08. The firm has a market cap of $9.31 million, a PE ratio of -0.62 and a beta of 0.93.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, August 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies.

Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.